Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in operating expenses and cash utilization as company prepares to scale neurorehabilitation products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 15, 2026 (GLOBE NEWSWIRE) — Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation...

Strategic First Quarter Investments Lay Foundation for Long-Term Growth NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s first AI-powered Preventative Personal Security platform adopted by leading multinational companies, today provided a business update and reported financial results for the first quarter of 2026 ended March 31, 2026. Business HighlightsStrong Enterprise Demand: Continued strong demand from enterprise customers, with deployments expanding across retail, telecommunications, financial services, pharmaceuticals and multinational organizations. Global Expansion: Expanded global footprint, with operations now spanning multiple regions, countries and languages. Multi-Channel Growth Strategy: Continued execution of Bond’s multi-channel go-to-market strategy...

SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter 2026 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fraction (BCDA-01)In February, PMDA provided additional questions for BioCardia, in line with those addressed and discussed in three preliminary...

OAKLAND, Calif., May 15, 2026 (GLOBE NEWSWIRE) — ContextLogic Holdings Inc. (OTCQB: LOGC) (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the first quarter ended March 31, 2026. Basis of Presentation  ContextLogic completed the acquisition of US Salt on February 26, 2026. To reflect the basis difference as a result of the US Salt acquisition, GAAP results for the first quarter of 2026 are presented in two parts: the period from January 1, 2026 through February 26, 2026 (“Predecessor”), reflecting legacy US Salt, and the period from February 27, 2026 through March 31, 2026 (“Successor”), reflecting ContextLogic Holdings Inc. and US Salt on a consolidated basis. To provide comparable period-over-period information, the Company also presents “Combined” results, a non-GAAP measure that aggregates...

Bayport Management Ltd Q1 2026 Financial StatementsAttachmentsGroup Quarterly report_March 2026Group Quarterly report_March 2026

Bayport Intermediate Holdco PLC Q1 2026 Financial StatementsAttachmentQuarterly report IH PLC_March 2026

Increased Government Sales Pipeline Driving Momentum Following Successful U.S. Army Exercises and Demonstrations in Q1 AVENTURA, Fla., May 15, 2026 (GLOBE NEWSWIRE) — Safe Pro Group Inc. (Nasdaq: SPAI) (Safe Pro or the Company), a developer of artificial intelligence (AI)-enabled defense, security, and situational awareness solutions, today announced financial results for the quarter ended March 31, 2026 reflecting the significant impact of a recently commercialized AI-powered Edge compute solution subcontract. First Quarter 2026 Financial and Recent Operational Highlights Include:Record Revenue Growth and High Margins Driven by AI Product SalesRecord quarterly revenue of $1,220,129 represents a 560% increase over $184,802 reported in the first quarter of 2025. Safe Pro AI quarterly revenue surged over 2,400%, driven by new...

– New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting –  – Pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line metastatic pancreatic cancer now recruiting (NCT07562152),with first patient dosing on track for mid-2026 – – 27 months progression-free survival to date in a third-line pancreatic cancer patient receiving atebimetinib monotherapy, with an ongoing 85% reduction in tumor burden – – Ended Q1 2026 with $198.6 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 – NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused...

DALLAS, May 15, 2026 (GLOBE NEWSWIRE) — Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update. Recent HighlightsInstil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates Cash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 2027“We continue to make progress refining Instil’s strategy and positioning the company for its next phase of growth,” said Bronson Crouch, Chief Executive Officer, Instil Bio. “We are actively evaluating a range of acquisition and in-licensing opportunities, with a focus on assets that align with our capabilities and...

All amounts in U.S. dollars unless otherwise stated TORONTO, May 15, 2026 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the first quarter ended March 31, 2026. Onex also released supplemental financial information for Convex Group Limited (“Convex”). “Onex carried significant momentum into 2026 and we continue to make good progress on our strategic objectives,” said Bobby Le Blanc, CEO. “Convex delivered another strong quarter of underwriting profitability and net income and remains well positioned for continued growth in 2026.” “Within Asset Management, following a strong period for Private Equity realizations last year, Onex Partners successfully closed on a $1.6 billion multi-asset continuation vehicle this quarter, delivering incremental return of capital and extending fee-generating...